RA Capital — Full Portfolio

Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.

BiotechHealthtechMedical Devices

GGreg(Co-founder & Senior Vice President of Discovery Research)MMark(Co-founder & Senior Vice President of Medicinal Chemistry)MMike(President & CEO)CCharlotte(Chief Medical Officer)EElena(Chief Financial Officer)CCaroline(Chief Business Officer)

Co-investorsATAtlas VentureOROrbiMed

Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.

BiotechHealthtechRadnor, US

Eric Warren(Chief Commercial Officer)inAGAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)

BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)OLOlivier Litzka(Director)in

Board seatDDDerek DiRocco· per SEC Form D

Co-investorsANAndera PartnersSASamsara BioCapitalSRSR One Capital ManagementYSYsios CapitalADAdams Street PartnersBOBoulder Ventures+1 more

Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.

BiotechCambridge, US

AMAnkit Mahadevia(Executive Officer, Director)inSGStephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in

BoardJFJean-Francois Formela(Director)inCasper Breum(Director)

Board seatReza Halse· per SEC Form D

Co-investorsHEHEALTHCARE ROYALTY PARTNERSMRMRL Ventures FundOUOUP (Osage University Partners)ALAlphabetATAtlas VentureFIFidelity Investments

Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.

BiotechHealthtechLongevitySingapore

TWTakeshi Wada(Director)inGLGregory L. Verdine(Director)PBPaul B. Bolno, M.D.(Executive Officer, Director)in

BoardKen Takanashi(Director)Masaharu Tanaka(Director)

Board seatPKPeter Kolchinsky· per SEC Form D

Co-investorsFOForesite Capital

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)SDStuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)inHDHugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)

Co-investorsAIAisling CapitalAPAPERTURE Venture PartnersF-F-Prime CapitalFOForesite CapitalSOSofinnova VenturesSOSofinnova Venture Partners+1 more

Adagio Medical develops and commercializes catheter-based cardiac ablation devices using proprietary Ultra-Low Temperature Ablation (ULTA) technology to treat ventricular tachycardia and other cardiac arrhythmias.

HealthtechLaguna Hills, US

Olav Bergheim(Executive Officer, Director)Andrew Wade(Executive Officer)HNHugh Neuharth(Executive Officer)TUTodd Usen(Chief Executive Officer and Director)inDeborah Kaster(Chief Financial Officer and Chief Business Officer)in

BoardMichael Zhao(Director)

Adagio Medical Holdings develops and commercializes catheter-based ablation devices using proprietary Ultra-Low Temperature Ablation technology to treat ventricular tachycardia, a life-threatening abnormal heart rhythm, primarily in patients with structural heart disease.

HealthtechLaguna Hills, US

TUTodd Usen(Executive Officer, Director)inDeborah Kaster(Executive Officer)in

BoardKeyvan Mirsaeedi-Farahani(Director)Orly Mishan(Director)James L. Cox(Director)Timothy P. Moran(Director)

Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.

BiotechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHGHalley Gilbert(Executive Officer)RDRebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)

Co-investorsFIFidelity InvestmentsFOForesite CapitalGVGV (Google Ventures)MIMITHRILMIMithril Capital ManagementOROrbiMed+3 more

Spyre Therapeutics develops monoclonal antibodies with extended half-lives targeting inflammatory bowel disease and rheumatic conditions including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

BiotechAustin, US

David G. Lowe(Executive Officer, Director)George Georgiou(Director)CNCharles N. York(Executive Officer)inCameron Turtle(Chief Executive Officer and Director)

BoardHenry Skinner(Director)Armen Shanafelt(Director)

Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.

BiotechHealthtechLexington, US

Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)RSRobert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)SOSteven O'Day(Chief Medical Officer)in

Co-investorsADAdvent Life SciencesGRGrazia Equity GmbHHEHEALTHCARE ROYALTY PARTNERSOBOberland CapitalCOCommodore CapitalINInvus+1 more

Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.

BiotechHealthtechMedical DevicesBoston, US

TFTodd Foley(Co-founder and Chairman)inPBPatrick Baeuerle(Co-founder & Advisor)inSRShulamit Ron-Bigger(Executive Officer)inKDKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPLPaul L. Feldman(Chief Scientific Officer)in

Co-investorsANAndreessen HorowitzECEcoR1 CapitalMPMPM BioImpactMRMRL Ventures FundPAPappas CapitalTCTCG Crossover+5 more

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.

BiotechHealthtechMenlo Park, US

Joseph S. Zakrzewski(Co-Founder & Director)EEEric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)SCSanjay Chanda(Chief Development Officer)inLOLucy O. Day(Chief Financial Officer)in

Co-investorsADAdjuvant CapitalBIBioRock VenturesFLFlucas VenturesMOMountain Group CapitalBIBiotechnology Value FundHAHatteras Venture Partners

Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.

BiotechHealthtechMedical Devices

MHMichael Henderson(Chief Executive Officer and Director)in

Co-investorsACAccess BiotechnologyBLBlackstone Life SciencesPEPerceptive Xontogeny VentureRTRTW Investments L.P.VEVenrock Healthcare Capital Partners

Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

BiotechHealthtechMedical DevicesWestlake Village, US

Todd Franklin Watanabe(Executive Officer, Director)Alexander Asam(Director)RSRicky Sun(Director)

BoardPHPatrick Heron(Director)inDEDaniel Estes(Director)inJonathan Silverstein(Director)

Co-investorsBABain Capital Life SciencesFRFrazier Life Sciences

Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.

BiotechHealthtechNew Haven, US

SCSean Cassidy(Executive Officer)inMLManuel Litchman(Executive Officer, Director)inRTRandy Teel(President and Chief Executive Officer; Director)in

BoardStephen Squinto(Director)inLRLiam Ratcliffe(Director)inTSTim Shannon(Director)in

Co-investors5A5AM VenturesACAccess BiotechnologyCACanaan PartnersCOConnecticut InnovationsNENextech InvestSOSolasta Ventures+1 more

Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).

BiotechHealthtechBoston, US

Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)Jean-Pierre Sommadossi(President, CEO and Chairman of the Board)inAndrea Corcoran(Chief Financial Officer, Executive Vice President, Legal, and Secretary)JHJanet Hammond(Chief Development Officer)inMaria Arantxa Horga(Chief Medical Officer)inJohn Vavricka(Chief Commercial Officer)in

Co-investorsBABain Capital Life Sciences

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.

Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)inDRDavid Raben(Chief Medical Officer)in

Co-investorsAIAisling CapitalEIEight Roads VenturesF-F-Prime CapitalFOForesite CapitalPRPremji InvestRERed Tree Venture+5 more

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

KFKristen Fortney, PhD(Co-Founder, CEO)EMEric Morgen, MD(Co-Founder, COO)KFKristen Fortney(Executive Officer, Director)inEMEric Morgen(Director)inDGDov Goldstein(Executive Officer)in

BoardPEPatrick Enright(Director)in

Co-investorsANAndreessen HorowitzELElad GilFEFelicis VenturesIAIA Seed VenturesLOLongitude CapitalOROrbiMed+5 more

Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy.

BiotechHealthtechMedical DevicesConnecticut, US

VCVlad Coric, M.D.(Chairman & Chief Executive Officer)in

Co-investorsOBOberland CapitalSISixth StreetBLBlackRock

Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.

EBElizabeth Buck(Chief Scientific Officer)inBrent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSYSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)

Co-investorsLALAVLILilly Asia VenturesNENew Enterprise Associates (NEA)NENextech InvestNSNSG VenturesVEVersant Ventures+3 more

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

DEDr. Edgar G. Engleman(Founder)

Co-investorsPFPfizer Venture InvestmentsSASamsara BioCapitalSOSofinnova VenturesVIVivo CapitalNANan Fung Life SciencesNONovo Holdings+3 more

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

BiotechMedical DevicesLa Jolla, US

ZDZachary D. Hornby(Executive Officer, Director)inRDRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)JOJessica Oien(Chief Legal Officer and Corporate Secretary)in

BoardBenjamin Cravatt, Ph.D.(Director)KBKristina Burow(Director)in

Co-investorsARARCH Venture PartnersNENextech InvestNENEXTECH ONCOLOGY SCSPSISignalFire

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.

BiotechCambridge, US

KCKenneth C. Anderson(Director)Andrew J. Hirsch(Director and Chief Executive Officer)in

BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)

Co-investors3E3E Bioventures CapitalBABain Capital Life SciencesNENextech InvestCOCobro Ventures

Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer.

AI & Machine LearningBiotechHealthtechMedical DevicesPhiladelphia, US

Osvaldo Flores, Ph.D.(Executive Officer, Director)Douglas Carr(Executive Officer)inBPBrent Pfeiffenberger(President and Chief Executive Officer)inGregory Russotti(Chief Technology and Manufacturing Officer)CCChad Cowan(Chief Scientific Officer)in

BoardToshikazu Ban(Director)

Co-investorsCACasdin CapitalVEVersant Ventures

Ceribell is a medical technology company that develops products for detecting and monitoring seizures, including EEG-based diagnostic systems.

AI & Machine LearningDigital HealthHealthtechMedical DevicesSunnyvale, US

JPJosef Parvizi(Director)inX(Xingjuan (Jane) Chao(President, CEO, Co-Founder & Director)inSBScott Blumberg(Executive Officer)inJoseph Taylor(Director)Raymond Woo(Executive Officer)David Stoffel(Executive Officer)

Co-investorsLOLongitude CapitalRERed Tree VentureSHShangBay Capital LLCTHThe Rise Fund

CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.

BiotechHealthtechMedical Devices

AKArthur Kuan(Chairman and Chief Executive Officer)in

Co-investorsDEDecheng CapitalFOForesite CapitalLOLongitude CapitalPAPalm Drive CapitalTCTCG CrossoverACACORN BIOVENTURES+2 more

Climbbio is a clinical-stage biotechnology company developing monoclonal antibodies targeting B-cell pathways for immune-mediated diseases including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.

ALAndrew Levin(Director)Aoife Brennan(President and Chief Executive Officer, Director)

Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.

BiotechCanton, US

MHMichael Heffernan(Executive Officer, Director)inPBPaul Brannelly(Executive Officer)inVKVikram Karnani(President and Chief Executive Officer, and Director)in

BoardEran Nadav(Director)John Freund(Director)PHPatrick Heron(Director)in

Co-investorsAPAPERTURE Venture PartnersECEcoR1 CapitalFRFrazier Life SciencesLOLongitude CapitalBOBoston Millennia Partners

Connect Biopharma is a clinical-stage biopharmaceutical company developing antibody-based therapies targeting inflammatory diseases such as atopic dermatitis and asthma.

BiotechHealthtechSan Diego, US

BDBarry D. Quart(Chief Executive Officer and Director)inDSDavid Szekeres(President)inKimberly J. Manhard(Executive Vice President, Chief Development Officer)in

Co-investorsCOCo-Win Ventures

Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.

BiotechSan Diego, US

Richard Scott Struthers(Executive Officer, Director)SFStephen F. Betz(Executive Officer)inSBStephen Betz(Chief Scientific Officer)inRSR. Scott Struthers(President, Chief Executive Officer and Director)inTSTobin Schilke(Chief Financial Officer)inIKIsabel Kalofonos(Chief Commercial Officer)in

Co-investors5A5AM VenturesFOForesite CapitalOROrbiMedVIVivo Capital

Cytek Biosciences develops high-parametric analytical instruments and software that enable scientists at pharmaceutical companies, contract research organizations, and academic institutions to generate and analyze biological datasets.

BiotechDeep TechHardwareHealthtechMedical DevicesBellevue, US

WJWenbin Jiang, Ph.D.(CEO and Chairman of the Board)Wenbin Jiang(Executive Officer, Director)inMYMing Yan, Ph.D.(Chief Technology Officer)Ming Yan(Executive Officer, Director)inJiecheng Zhang(Director)Allen Poirson(Director)

Co-investors3E3E Bioventures CapitalF-F-Prime CapitalNONorthern Light Venture Capital

Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.

BiotechCopenhagen, US

GWGarrett Winslow(Executive Officer)inLFLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)

Co-investorsACAccess BiotechnologyBABAM ElevateBABay City CapitalCOCommodore CapitalEIEIR VenturesFOForbion+6 more

Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.

BiotechMedical DevicesSolana Beach, US

PSPratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)SJSean Jeffries, Ph.D.(Executive Officer)

BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)

Co-investorsAVAvoro Capital AdvisorsQUQuan CapitalSRSR One Capital ManagementWEWestRiver GroupQUQuan Venture

CervoMed is a clinical-stage biopharmaceutical company developing neflamapimod, an investigational drug for neurodegenerative diseases such as nonfluent variant primary progressive aphasia and frontotemporal dementia.

BiotechHealthtechCharlottesville, US

John L. Gainer(Executive Officer, Director)inDavid G. Kalergis(Executive Officer, Director)inDavid R. Jones(Executive Officer)inBen L. Shealy(Executive Officer)John Moynahan(Executive Officer)Stephen Simes(Executive Officer, Director)

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOBOxana Beskrovnaya, Ph.D.(Executive Officer)JGJohn G. Cox(Chief Executive Officer and President, Director)in

Co-investorsATAtlas VentureMPMPM BioImpactVIVida VenturesFOForbionHEHercules Capital, Inc.

Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.

BiotechWilmington, US

Valerie Morisset(Executive Officer)inErin Lavelle(Executive Officer)inRobert Azelby(Executive Officer, Director)James Bucher(Executive Officer)Leone Patterson(Director)

BoardAdam Rosenberg(Director)

Co-investorsMAManta Ray VenturesACAccess BiotechnologyACACORN BIOVENTURES

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.

BiotechHealthtechBoulder, US

Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHCHelen Collins(Chief Medical Officer)inBHBen Hohl(Chief Financial Officer and Head of Corporate Development)in

Co-investors5A5AM VenturesOROrbiMedPFPfizer Venture InvestmentsRORoche Venture FundARARCH Venture PartnersBABay City Capital+1 more

A pharmaceutical company whose executive team emphasizes innovation and patient care.

BiotechDigital HealthMental Health

Co-investorsFOForesite Capital

Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsACAccess BiotechnologyAVAvoro Capital AdvisorsHEHealthCapNONovo HoldingsSOSofinnova PartnersAVAvoro Ventures

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.

BiotechCambridge, US

JGJames G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)

Co-investorsBABay City CapitalNENew Enterprise Associates (NEA)ALAlexandriaARArix BioscienceLULundbeckfonden VenturesOROrbiMed+2 more

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

MEMarc Elia(Founder)in

Co-investorsBABain Capital Life SciencesFOForesite CapitalMRMRL Ventures FundPRPremji InvestGVGV (Google Ventures)MIMITHRIL+3 more

A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.

BiotechArlington, US

JHJustin Hanes(Director)inKPKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTBTodd Bazemore(Executive Officer)inMIMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in

Co-investorsLOLongitude CapitalSRSR One Capital ManagementYSYsios CapitalATAtlas VentureLULux CapitalTHThird Rock Ventures

Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology imaging and treatment of advanced solid tumors, along with ALXN1840, a late-stage investigational treatment for Wilson Disease, a rare genetic disorder.

BiotechHealthtechMedical DevicesLake Forest, US

CDChandler D. Robinson(Executive Officer, Director, Promoter)inCMChristopher M. Starr(Executive Officer, Director)Andrew P. Mazar(Executive Officer, Director)

BoardMichael J. Brown(Director)

Co-investorsJAJanus Henderson Investors

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

MRMatthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)

Co-investorsBABain Capital Life SciencesCHCheyenne VenturesCLClaremont Creek VenturesFOForesite CapitalHAHarmony PartnersLILightspeed Venture Partners+2 more

Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.

BiotechHealthtechSouth San Francisco, US

PHPaul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)inPJPaul J. Hastings(Chief Executive Officer)in

BoardMichael Dybbs(Director)JCJill Carroll(Director)in

Co-investorsNENew Enterprise Associates (NEA)SASamsara BioCapitalSRSR One Capital ManagementAMAmgen VenturesLOLogosNONorwest Venture Partners+1 more

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.

BiotechHealthtechSan Francisco, US

Cyrus L. Harmon, Ph.D.(Director)Cyrus Harmon(Executive Officer, Director)inCLCyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)in

Co-investorsAVAvoro Capital AdvisorsBABain Capital Life SciencesFOForesite CapitalLILightspeed Venture PartnersBIBiotechnology Value FundLOLogos+1 more

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

MMMathai Mammen(CEO, President and Chairman)in

Co-investorsARARCH Venture PartnersCACatalio Capital Management, LPFOForesite CapitalFRFrazier Life SciencesGEGeneral CatalystNENextech Invest+7 more

PepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.

AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US

JMJames McArthur(Executive Officer, Director)inNPNoel P. Donnelly(Chief Financial Officer)inJDJoseph D. Vittiglio(Chief Business & Legal Officer and Secretary)inKKKasra Kasraian(Chief Technical Officer)in

BoardRFRamin Farzaneh-Far(Director)inJoshua Resnick(Director)

Co-investorsOXOxford Science Enterprises

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

BiotechDeep TechHealthtechDurham, US

DJDEREK JANTZ(Executive Officer, Director)inMKMATTHEW KANE(Executive Officer, Director)JSJeff Smith(Co-founder)inDJDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMAMichael Amoroso(President, Chief Executive Officer)in

Co-investorsAGage1AGAgent CapitalALAliment CapitalBRBrace PharmaF-F-Prime CapitalOCOCV Partners+4 more

Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.

BiotechHealthtechMilpitas, US

Dinesh V. Patel, PhD(Executive Officer, Director)DPDinesh Patel(President & Chief Executive Officer)

BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)

Co-investorsAIAisling CapitalCACanaan PartnersJJJJDCJOJohnson & Johnson Innovation – JJDCLILilly VenturesSTStarfish Ventures

Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins.

BiotechDun Laoghaire, Co. Dublin, US

TBTran B. Nguyen(Executive Officer)Arthur W. Homan(Executive Officer)KLKarin L. Walker(Executive Officer)inTara Nickerson, Ph.D.(Executive Officer)Wagner M. Zago, Ph.D.(Executive Officer)CDCarol D. Karp(Executive Officer)in

Co-investorsSOSofinnova VenturesINInvescoWEWellington Management

Pyxis Oncology is a clinical-stage biotech company developing antibody-drug conjugates for solid tumors, with its lead candidate targeting a fibronectin variant found in tumor tissue but not healthy tissue.

HealthtechBoston, US

Thomas Civik(Interim Chief Executive Officer, Director)

BoardDSDavid Steinberg(Executive Officer, Director)inCWChristoph Westphal(Director)GVGeeta Vemuri(Director)inJak Knowles(Director)John Flavin(Director)

Co-investorsAGAgent CapitalLOLongwood FundRTRTW Investments L.P.

Rani Therapeutics develops oral drug delivery technology using robotic capsules to replace injectable biotherapeutics, addressing the challenge of delivering biologics through the gastrointestinal tract without needles.

BiotechDigital HealthHealthtechMedical DevicesSan Jose, US

MHMir Hashim(Executive Officer, Director)inTITalat Imran(Chief Executive Officer)in

BoardMir Imran(Founder)AFAndrew Farquharson(Director)in

Co-investorsINInCube VenturesVHVHM

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for biologics and drugs, primarily through its proprietary RaniPill capsule platform, which comes in two configurations (RaniPill GO for up to 3 mg microtablet doses and RaniPill HC for up to 200µL liquid doses).

BiotechSan Jose, US

TITalat Imran(Executive Officer, Director)inSSSvai Sanford(Executive Officer)inMir Hashim(Executive Officer)in

BoardAbraham Bassan(Director)Vasudev Bailey, M.D.(Director)Mir Imran(Director)

Co-investorsINInCube Ventures

Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.

BiotechHealthtechNew York, US

Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEOEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)

Co-investorsBIBioAdvanceBABAM ElevateBRBraidwellCOCommodore CapitalJAJanus Henderson InvestorsOROrbiMed+2 more

RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.

HealthtechMedical DevicesPasadena, US

Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)inRKRon Kurtz(President, Chief Executive Officer & Director)MWMark Wilterding(Chief Financial Officer)in

Co-investorsFLFlying L PartnersFOForesite CapitalH.H.I.G. CapitalH.H.I.G. HealthBridge PartnersLOLongitude CapitalVIVisionary Ventures+2 more

Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.

BiotechDeep TechHealthtechMedical DevicesBerkeley, US

BOBenjamin Oakes(Founder & CEO)inJAJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)BLBenjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)BSBrett Staahl, PhD(Co-founder, VP of External Innovation)

BoardVPVijay Pande(Director)in

Co-investorsANAndreessen HorowitzOROrbiMedAVAvoro Capital AdvisorsMEMenlo VenturesAVAvoro Ventures

SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections.

BiotechDurham, US

Yves J. Ribeill(Executive Officer, Director)inCharles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)inDADavid Angulo(Chief Executive Officer, President and Director)in

BoardLaurent Arthaud(Director)Mounia Chaoui(Director)

Co-investorsDEDecheng CapitalFOForesite CapitalDEDeerfield Management Company

Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

MHMatthew Henn(President and Chief Scientific Officer)inJohn Aunins(Executive Officer)inEDEric D. Shaff(Executive Officer)inDCDavid Cook(Executive Officer)inRJRoger J. Pomerantz(Executive Officer, Director)inRichard N. Kender(Executive Chair and Interim Chief Executive Officer)

Co-investorsFLFlagship PioneeringSOSofinnova VenturesFIFidelity Investments

Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.

BiotechHealthtechCharlestown, US

IGIlan Ganot(Co-Founder and Director)inStephen DiPalma(Executive Officer)CMCarl Morris(Executive Officer)inAlexander Cumbo(President, Chief Executive Officer and Director)MFMartin Freed(Director)inPaul Herizch(Executive Officer)

Co-investorsBABain Capital Life SciencesFOForesite Capital

SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation.

BiotechHealthtechMedical DevicesAliso Viejo, US

GSGlenn Sussman(Co-founder)inMYMalik Y. Kahook(Co-founder)inPMPatrick Mooney(CEO)

BoardJake Merrill(Director)GPGeoff Pardo(Director)BKBilal Khan(Director)

Co-investorsNENew Enterprise Associates (NEA)SASamsara BioCapitalSASands Capital VenturesVEVensana Capital

BiotechSouth San Francisco, US

Grant E. Pickering(Chief Executive Officer)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)

BoardTracy Saxton(Director)William Newell(Director)KVKurt von Emster(Director)in

Co-investorsABAbingworthCTCTI Life Sciences Fund L.P.FOForesite CapitalFRFrazier Life SciencesJAJanus Henderson InvestorsLOLongitude Capital+4 more

Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.

BiotechHealthtechCarlsbad, US

Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)inAlan Fuhrman(Executive Officer)inTHTodd Harris(President, Chief Executive Officer and Director)inBhavesh Ashar(Chief Operating Officer)in

Co-investorsALAlta PartnersBIBioBritNENextech InvestCACanaan PartnersNENEXTECH ONCOLOGY SCSP

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

GPGrant Pickering(Founder)inGEGrant E. Pickering(Chief Executive Officer and Director)in

Co-investorsBIBioRock VenturesCTCTI Life Sciences Fund L.P.FOForesite CapitalFRFrazier Life SciencesLOLongitude CapitalJAJanus Henderson Investors+2 more

Vor Biopharma is a biopharmaceutical company.

BiotechCambridge, US

Nathan Jorgensen(Executive Officer)Amy Mendel(Executive Officer)RARobert Ang(Executive Officer, Director)JKJean-Paul Kress(President, Chief Executive Officer and Chairman of the Board)in

BoardKPKush Parmar(Director)inJoshua Resnick(Director)

Co-investors5A5AM VenturesOUOUP (Osage University Partners)PUPureTech Health

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

RRRené Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKLKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)

Co-investorsBABain Capital Life SciencesBABay City CapitalF-F-Prime CapitalM M VenturesMRMRL Ventures FundRIRiverVest Venture Partners+9 more

Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.

BiotechHealthtechMedical DevicesAustin, US

Shanshan Xu(Founder & Chief Executive Officer)inHJHelmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)inCMCrystal MacKay(Chief Operating Officer)in

Board seatDDDerek DiRocco· per SEC Form D

Co-investorsININCE CapitalSASalviaBIBiotechnology Value FundJAJanus Henderson InvestorsREREDMILE

Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.

BiotechDeep TechMedical DevicesSeattle, US

MLMarc Lajoie(Co-founder & Chief Executive Officer)inSBScott Boyken(Co-founder & Chief Innovation Officer)inStanley Riddell(Co-Founder and Scientific Advisor)AFAaron Foster(Executive Officer)inCharity Scripture(Executive Officer)inESEric Soller(Executive Officer)in

Board seatJSJake Simson· per SEC Form D

Co-investorsARArtis VenturesABAbstract VenturesATAtinum Investment Co. Ltd.CICivilization Ventures Management, LlcMOModi VenturesPLPlayground Global+1 more

Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.

BiotechHealthtechCambridge, US

ARAaron Ring(Co-founder)inAMAashish Manglik(Co-founder)inJeff Landau(Chief Executive Officer)inRGRoland Gendron(Chief Business Officer)inMZMichelle Zhang(Chief Scientific Officer)in

BoardVAVineeta Agarwala(Director)in

Board seatDDDerek DiRocco· per SEC Form D

Co-investorsANAndreessen HorowitzMAMagnetic VenturesOMOMX VenturesAXAxial VCGVGV (Google Ventures)LOLoLa Capital Partners+1 more

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBABain Capital Life SciencesNENew Enterprise Associates (NEA)SASamsara BioCapitalSASanofi VenturesMAMass General Brigham VenturesREREDMILE+9 more

Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.

BiotechHealthtechMedical Devices

JEJack Elands(Founder & CEO)inXPXavier Preville(Co-founder, VP & Head of Research & Preclinical Development)inJHJan H.M. Schellens(Chief Medical Officer)inTMThierry Menguy(VP & Head of CMC Operations)inJAJaime Arango(Chief Financial Officer)inPJPaul Jackson(Chief Operating Officer)in

Co-investorsAMaMoonBPBpifranceANAndera PartnersANAngelini VenturesKUKurma PartnersPOPontifax Venture Capital+1 more

Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.

AI & Machine LearningBiotechDeep TechHealthtech

JOJane Osbourn(Chief Executive Officer)

Co-investorsSVSV Health InvestorsDCDCVC BioDEDementia Discovery FundLILightstone VenturesONOno Venture Investment, Inc.BRBritish Business Bank+2 more

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.

AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH

TBThomas Baumert(Founder)inMPMark Pruzanski(Chief Executive Officer)inLMLuigi Manenti(Chief Medical Officer)inJFJon Freve(Chief Financial Officer)inBYBryan Yoon(General Counsel and Chief Administrative Officer)inAVAditya Venugopal(Chief Business Officer)in

Co-investorsAVAvego BioScience CapitalBIBioMedPartnersFRFrazier Life SciencesJEJeito CapitalLOLongitude CapitalNONovo Holdings+5 more

Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.

BiotechHealthtechMedical Devices

Bryan E. Stuart(Chief Executive Officer)inMDMarion Dorsch(President and Chief Scientific Officer)in

Co-investorsLULux CapitalTHThe Column GroupNENextech Invest

Avalanche Energy develops compact fusion technology to generate high-energy neutrons for materials testing, radioisotope production, and advanced nuclear battery systems serving defense, space, and commercial power applications.

Deep TechDefense TechEnergyRichland, US

Robin Langtry(Co-Founder, CEO)inBRBrian Riordan(Co-Founder, COO)in

Co-investorsCOCongruent VenturesFOFounders FundLOLowercarbon CapitalTOToyota VenturesAUAutodesk FoundationAZAzolla Ventures+4 more

Bia is a technology-driven electricity retailer in Colombia that lets businesses switch their energy provider and replace traditional meters with its proprietary BiaMonitor smart meter.

CleantechEnergyIoTBogota, CO

SRSebastian Ruales(Founder)inGuillermo Plaza Roche(Director)Leonardo Velazquez Florez(Director)Juan Sebastian Ruales Duque(Director)JEJaime E. Zunzunegui(Director)in

BoardNBNicolas Berman(Director)in

Co-investorsBBBBVA SPARKIDIDB LabKAKaszek VenturesMAMarathon VenturesNANazcaNONorte Ventures+4 more

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.

BiotechHealthtechSan Diego, US

VPVijaya Pattabiraman(Co-founder & Chief Technology Officer)inJBJeffrey Bode(Scientific co-founder; Professor at ETH Zürich)inFWFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)MRMichael Rosenzweig(Director)Bertolt Kreft(Executive Officer)

Co-investorsJOJohnson & Johnson Innovation – JJDCVEVersant VenturesVEVenrockALAlexandriaBLBlackRockFIFidelity Investments+2 more

Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria.

BiotechDeep TechLongevityPalo Alto, US

AWAmy Wang(PhD)inKHKenneth Horne(Executive Officer, Director)inDMDylan Morris(Director)inCGCristina Ghenoiu(Director)in

BoardTITaro Inaba(Director)in

Co-investorsRERemiges Ventures, Inc.INInsight PartnersANAN Venture PartnersRDRDiscovery

CDR-Life develops T cell engager immunotherapies for cancer and autoimmune diseases using its M-gager antibody platform, targeting both conventional tumor antigens and hard-to-treat targets.

BiotechHealthtechHorgen, CH

Rouven Bingel-Erlenmeyer(Founder)inCLChristian Leisner(Co-founder)inDEDominik Escher(Co-founder)

Co-investorsJEJeito Capital

Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.

BiotechHealthtechMedical DevicesSuzhou, CN

WWWilliam Wei Caoin

Co-investorsLALAVLILilly Asia VenturesOROrbiMedEXExome Asset ManagementJAJanus Henderson InvestorsPIPivotal Life Sciences+2 more

Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.

BiotechDeep TechMedical DevicesBurlington, US

KCKLEEM CHAUDHARY(Executive Officer, Director, Promoter)inK(Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)KCKleem Chaudhary, PhD(President & CEO)

BoardJOHN GUSTOFSON(Director)LBLAURA BRASS(Director)inLTLAURA TADVALKAR(Director)in

Co-investorsDRDroia VenturesEIEisai Innovation, Inc.NONovartis Venture Fund

Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases.

BiotechHealthtechHouston, US

GDGuy DiPierro(Chief Operating Officer & Co-Founder)inSungjin Kim(Scientific Founder)John Sunwoo(Scientific Founder)MWMark W. Frohlich(Chief Executive Officer)Stefanie Mandl-Cashman(Acting Chief Scientific Officer)

BoardLori Hu(Director)in

Co-investorsLELeaps by BayerVEVertex Ventures HC

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.

BiotechHealthtechMedfield, US

RHRoger Heerman(Chief Business/Operating Officer / Co-Founder)inFMFrazer Morgan(Chief Development Officer / Co-Founder)inRCRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)

BoardJBJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)

Co-investors5A5AM VenturesATAtlas VentureEQEQT Life SciencesSISixty Degree CapitalVIVivo CapitalGIGimv+3 more

MMI develops miniaturized robotic surgical instruments and platforms to enable surgeons to perform complex microsurgery and supermicrosurgery on delicate anatomical structures with greater precision.

HealthtechMedical DevicesRoboticsJacksonville, US

MTMark Toland(Executive Officer, Director)inAndrew Cleeland(Director)Justin Lynch(Director)inTheresa Jean Cameron(Director)Caleb Moore(Executive Officer)Augusto Vianna Castello(Director)

Co-investorsANAndera PartnersBIBioStar CapitalDEDeerfield Management CompanyFIFidelity InvestmentsCOCorewell Health VenturesFOFountain Healthcare Partners

PAhR Therapeutics is a clinical-stage biotech company developing novel mechanisms to treat pulmonary arterial hypertension (PAH).

BiotechHealthtech

Co-investorsANAN Venture PartnersUTUTEC

Pluton is developing a sun-powered, soil-surface biological nutrient system that uses photosynthetic microbial consortia to fix atmospheric nitrogen, improve phosphorus availability, and add carbon to soil for crop growers.

AgTechBiotechClimate TechSt. Louis, US

Barry Goldman(Co-founder)inElizabeth Gallegos(Chief Executive Officer)inJSJerry Steiner(Executive Chair)inCWCharlie Walch(Executive Officer, Director)inGlendon Schuster(Director)

Co-investorsFIFirst In VenturesILIllumina VenturesRARadicle GrowthBEBetter VenturesFAFall Line CapitalGRGrantham Foundation+4 more

Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.

BiotechDigital HealthDel Mar, US

PJPatrick Johnson(Executive Officer, Promoter)inMary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)

Co-investorsLOLongitude CapitalVIVisionary Ventures

Synolo Therapeutics develops conditionally-active immunotherapies for treating cancer, using a proprietary discovery platform to build a pipeline of oncology drug candidates.

BiotechHealthtech

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

PTPatrick Trojer(President & Chief Executive Officer)in

Co-investorsASAscenta CapitalATAtlas VentureLILightspeed Venture PartnersBEBessemer Venture PartnersPFPfizer VenturesPFPfizer Venture Investments+2 more

Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.

BiotechDeep TechMedical Devices

George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in

Co-investorsPFPfizer VenturesSASamsara BioCapitalSVSV Health InvestorsPFPfizer Venture InvestmentsM M Ventures

Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types.

BiotechHealthtechMedical DevicesSan Mateo, US

Shuang Qiao(Executive Officer, Director)Sheng Ding(Executive Officer)

BoardEdward Hu(Director)JWJun Wu(Director)JSJake Simson(Director)inTSTim Shannon(Director)in

Co-investorsCACanaan PartnersCECenova CapitalMIMission Biocapital

Voro Metals operates a patent-pending pyrometallurgical process that removes residual copper and other contaminant metals from recycled scrap steel, upgrading low-grade feedstock into higher-value material.

Circular EconomyCleantechNew Materials

Acrivon is a clinical-stage oncology company developing precision medicine therapeutics for cancer treatment, using its proprietary AP3 proteomics platform to create companion diagnostics that match patients to drugs based on tumor-driving mechanisms.

AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US

PBPeter Blume-Jensen(Executive Officer, Director)KMKristina Masson(Executive Officer, Director)EGerick gamelininEDEric Devroe(Executive Officer)in

BoardMarcin Czernik(Director)Sharon Shacham(Director)

Board seatDDDerek DiRocco· per SEC Form D

Co-investorsNENew Enterprise Associates (NEA)PUPureos Bioventures

ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.

BiotechHealthtechMedical DevicesSan Diego, US

Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)

BoardJonathan Leff(Director)

Board seatPKPeter Kolchinsky· per SEC Form D

Co-investorsNENextech InvestOROrbiMedSRSR One Capital Management

Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.

BiotechHealthtechMedical DevicesSan Diego, US

Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)FAFred Aslan(Executive Officer, Director)inJLJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)PFPeter Flynn(Executive Officer)in

Board seatLSLaura Stoppel· per SEC Form D

Co-investors5A5AM VenturesECEcoR1 CapitalVEvenBio PartnersVEvenBio Global Strategic

Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.

BiotechHealthtechSouth San Francisco, US

Jeremy Bender(Executive Officer, Director)

BoardMGMichael Gladstone(Director)inJulie Papanek Grant(Director)inJJJohn Josey(Director)inDaniel Becker(Director)

Board seatDDDerek DiRocco· per SEC Form D · $130M raise · filed Feb 2021

Co-investorsACAccess BiotechnologyATAtlas VentureCACanaan PartnersACAccess IndustriesTHThe Column Group

Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.

BiotechHealthtechPalo Alto, US

LPLuis Pena(Executive Officer, Director)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)

Board seatDDDerek DiRocco· per SEC Form D

Co-investorsANAndera PartnersAVAvego BioScience CapitalB B Capital GroupB4B4 CapitalBEBeiersdorf Innovation FundFEFemHealth Ventures+3 more

G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.

BiotechResearch Triangle Park, US

Jay Strum(Executive Officer)NSNorman Sharpless(Director)Mark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)

Board seatPKPeter Kolchinsky· per SEC Form D

Co-investorsLULumira VenturesMOMountain Group CapitalSOSolasta VenturesHAHatteras Venture Partners

BiotechSeattle, US

Charles Richardson(Senior Vice President, Technical Operations)Adam K. Simpson(President and Chief Executive Officer)Niranjan Kanesa-thasan(Chief Medical Officer)Douglas A. Holtzman(Chief Scientific Officer and Secretary)Cassia Cearley(Treasurer, Chief Business Officer)

Board seatPKPeter Kolchinsky· per SEC Form D

Co-investorsSASanofi VenturesQIQiming Healthcare

Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.

BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US

Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)ACAllen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)JDJayson Dallas(Executive Officer, Director)inSKShaharyar Khan(Co-founder & Chief Scientific Officer)in

BoardFDFrancesco De Rubertis(Director)in

Board seatDDDerek DiRocco· per SEC Form D · $57M raise · filed Jan 2025

Co-investorsMEMedicxiBABain Capital Life SciencesLOLongitude Capital

Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.

AI & Machine LearningBiotechDeep TechSouth San Francisco, US

Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)RXRan Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)SSSamira Shaikhly(Executive Officer)in

Board seatJSJake Simson· per SEC Form D

Co-investorsCACatalio Capital Management, LPSASamsara BioCapitalVEVertex Ventures HCTHThird Rock Ventures

Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.

BiotechHealthtechMedical DevicesWatertown, US

Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)LELuke Evnin(Co-founder, Board member (Chairman))inDaniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)Alon Lazarus(Director)

BoardCWChristoph Westphal(Director)

Board seatDDDerek DiRocco· per SEC Form D

Co-investorsDCDC Investment PartnersK2K2 HealthVenturesLOLongwood FundMPMPM BioImpactTATaiho Ventures, LLC

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.

BiotechMedical Devices

Co-investorsVIVida VenturesHEHealthCapJEJeito CapitalNONovo HoldingsOROrbiMedPOPontifax Venture Capital+2 more

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsBABain Capital Life SciencesSOSofinnova Ventures

Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery.

AI & Machine LearningBiotechHealthtechNew York, US

Martin Vogelbaum(CEO, co-founder)inRoss Levine(Director)Ramy Farid(Director)

BoardScott Platshon(Director)

Co-investorsINInning One VenturesECEcoR1 CapitalVIVivo Capital

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

ESEmmanuel Simons(Executive Officer, Director)WSwilliam sewell(Founder)in

BoardEd Mathers(Director)inKPKush Parmar(Director)in

Co-investors5A5AM VenturesECEcoR1 CapitalNENew Enterprise Associates (NEA)SOSofinnova VenturesCOCowen Healthcare InvestmentsFIFidelity Investments+1 more

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

FBFrançois Bénard(MD)KLKuo-Shyan Lin(PhD)DPDavid Perrin(PhD)

Co-investorsANAndreessen HorowitzASAscenta CapitalDEDelos CapitalGEGeneral CatalystLILightspeed Venture PartnersLOLongitude Capital+9 more

AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.

BiotechHealthtech

Co-investorsAMaMoonDEDelos CapitalBIBiotechnology Value FundSOSoleus Capital

AM Batteries develops Powder to Electrode dry coating technology for lithium-ion electrode manufacturing, reducing solvent use and energy consumption compared to traditional slurry methods.

Advanced ManufacturingCleantechEnergyMassachusetts, US

YWYan Wang(Director)in

BoardAAAnil Achyuta(Director)inJKJimmy Kan(Director)inLCLisa Coca(Director)inLSLie Shi(Director)in

Co-investorsANAnzu PartnersCRCreative VenturesFOFoothill VenturesASAsymmetric Capital PartnersBRBreakthrough Energy VenturesTDTDK Ventures+1 more

Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

BiotechDeep TechMedical DevicesEindhoven, US

COChristian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)

Co-investorsDRDroia VenturesMIMission BiocapitalMRMRL Ventures FundNENextech InvestINInkef

Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.

Biotech

Co-investorsASAscenta CapitalFRFrazier Life SciencesOROrbiMedFRFrazier

Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods.

BiotechDeep TechHealthtechEmeryville, US

DLDan Lin-Arlow(Founder)inSPSebastian Palluk(Founder)inDaniel Lin-Arlow(Executive Officer, Director)inDHDaniel Hillel Lin-Arlow(Executive Officer, Director)JTJason T. Gammack(Executive Officer, Director)in

BoardYanniv Dorone(Director)

Co-investorsCACarbon SiliconCECerberus VenturesDADauntless VenturesFIFifty YearsMEMetaplanetY Y Combinator+3 more

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)DMDouglas Mayers(Executive Officer)inTATamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAIAisling CapitalALAltium CapitalAVAvego BioScience CapitalPOPontifax Venture CapitalAMAmzak HealthDEDelos Capital+8 more

Apeiron Labs develops autonomous underwater vehicles and ocean technology for marine applications.

Climate TechDeep TechIoTRoboticsCambridge, US

RPRavi Pappu(CEO / Board Member)in

BoardSKSanjeev Krishnan(Director)Jonathan Rosen(Director)David Douglas(Director)Kyle Teamey(Director)inMark Abbott(Director)

Co-investorsBABay Bridge Ventures ClimateCOCoalitionS2S2G InvestmentsTFTFX CapitalBRBreakthrough Energy Ventures

Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.

BiotechHealthtechMedical Devices

Co-investorsANAndera PartnersM M VenturesNONovartis Venture FundPFPfizer Venture InvestmentsSOSofinnova PartnersSVSV Health Investors+2 more

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

JMJan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)MAMartin Auster(Executive Officer)in

Co-investorsVIVivo CapitalAIAisling CapitalAVAvoro Capital AdvisorsFOForesite CapitalSOSofinnova Ventures

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

IDIvana Djuretic(Founder)inAYAndy Yeung(Founder)in

Co-investorsEMEmles Venture PartnersGOGoAhead VenturesMIMission Bay CapitalMIMission BiocapitalY Y CombinatorALAlexandria+4 more

BiotechSan Francisco, US

MPMatthew Patterson(Executive Officer, Director)in

BoardJSJonathan Silverstein(Director)inSteve Squinto(Director)inKPKush Parmar(Director)inJonathan Leff(Director)Thomas Woiwode(Director)

Co-investorsASAsset Management CompanyVEvenBio Partners5A5AM VenturesDEDeerfield Management CompanyOROrbiMedVEVenrock

Avalanche provides software development tools that startups can integrate to build and operate referral programs within their products.

Enterprise SoftwareMarketing TechSan Francisco, US

E(Elezhan (Ijan) Zhakiya(Founder)in

Co-investorsLOLowercarbon CapitalY Y Combinator808090 IndustriesCOCongruent VenturesFOFounders FundTOToyota Ventures

The Avalanche Foundation is a non-profit organization that supports innovation and growth in the Avalanche ecosystem through grants, programs, and strategic support for developers, entrepreneurs, and communities building on the Avalanche blockchain platform.

Crypto & Web3Data & InfrastructureDeveloper ToolsEnterprise SoftwareFintech

EGEmin Gun Sirer(Founder)in

Co-investorsA1a16z cryptoAEAegis VentuesANAndreessen HorowitzANAndromeda CapitalBABaseTwoBIBig Brain Holdings+25 more

Ava Labs is a company building blockchain infrastructure and tools for creating and using finance applications.

Crypto & Web3Data & InfrastructureDeep TechFintechNew York City, US

EGEmin Gün Sirer(Founder & CEO)in

Co-investorsANAnimoca BrandsABAbstract VenturesCECeras VenturesCOContinue CapitalLVLvna Capital808090 Industries+5 more

Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.

BiotechWaltham, US

THERESA CAMERON(Director)MFMARTIN FREED(Director)inSTEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MDMILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)

Co-investorsASAstellas Venture Management LLCMEMedical Excellence CapitalSASanofi VenturesOPOpenSky Ventures

Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.

AI & Machine LearningBiotechMedical DevicesSan Francisco, US

JDJennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)CTConnor Tsuchida(Scientific Cofounder)in

Co-investorsTHThird Rock VenturesSOSozo VenturesYOYosemite

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.

BiotechLongevityMedical DevicesCambridge, US

DMDavid Meek(Chief Executive Officer)inBRBrian Riley(President & Chief Technical Officer)inJLJoanne Lager(Chief Medical Officer)inWDWendy DiCicco(Chief Financial Officer)inACAdrian Chaisson(Chief of Staff)inJCJason Cole(Executive Officer)

Co-investorsARARCH Venture PartnersEAEaston CapitalSASanofi Ventures

Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.

San Mateo, US

KCKeting Chu(Executive Officer, Director)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)

Co-investorsFRFrazier Life SciencesRIRiverVest Venture PartnersFRFrazier Healthcare PartnersHBHBM Healthcare InvestmentsNONovo HoldingsT.T. Rowe Price+1 more

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Nick Lydon(Director)CSChristoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in

BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)

Co-investorsF-F-Prime CapitalFOForesite CapitalNENextech Invest

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical DevicesSan Diego, US

ABAdrian Bot(Executive Officer)LSLaura Shawver(Executive Officer, Director)inRFRamin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Co-investorsPFPfizer Venture InvestmentsSOSofinnova VenturesVIVida Ventures

Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.

BiotechHealthtechMedical Devices

Co-investorsPUPureTech HealthLELeaps by Bayer

CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers.

BiotechHealthtechMedical Devices

Azim Surani(Co-founder)

Co-investorsAVAvego BioScience CapitalFUFuture Planet CapitalBRBrightEdgeFOForbionVEVenrock

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

JSJeffrey Stein(Executive Officer, Director)KJKevin Judice(Director)inKevin Forrest(Executive Officer)DTDirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPDPaul Daruwala(Executive Officer)in

Co-investors5A5AM VenturesAIAisling CapitalBABain Capital Life SciencesFRFrazier Life SciencesVIVivo CapitalCACanaan Partners+1 more

BiotechChelsea, US

RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)inMIMARK IWICKI(Executive Officer, Director)inMFMARTIN FREED(Executive Officer)in

BoardRHROB HOPFNER(Director)in

Co-investorsCACanaan PartnersSOSofinnova VenturesBABay City CapitalLOLongitude CapitalOROrbiMed

Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.

BiotechHealthtechMedical DevicesJersey City, US

CAClarke Atwell(Co-Founder and Chief Operating Officer)inHenry Rath(Executive Officer)SOSusan Orr(Executive Officer)inStephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)

Co-investorsCACatalio Capital Management, LPSOSofinnova VenturesCACatalio Capital ManagementNONovo HoldingsSASamsara BioCapital

Climb is a French wealth management service that combines advisors with technology to grow clients' assets through an open-architecture selection of investment products (life insurance, retirement PER, real estate, private equity, tax-reduction schemes, crypto).

FintechSaaS

AEAldric Emié(CEO)in

Co-investorsKIKima VenturesALAlly Bridge GroupREREDMILE

Commons produces CBD gummies marketed for relaxation and wellness purposes, sold direct-to-consumer through their online store.

ConsumerDirect to ConsumerWellness & Fitness

BoardTahira

Co-investorsEMEmles Venture PartnersCOCourtside VenturesFLFloating PointSTSteelSky VenturesTITime BioVentures

Commons Clinic is an orthopedic care provider offering treatment for spine, joint, and sports medicine conditions, along with preventive health services such as full-body MRI and biomarker labs.

Digital HealthHealthtechWellness & FitnessAustin, US

BHBrad Hively(Director)inNANick Aubin(Founder)inPaulo Marques Da Costa(Executive Officer, Director)PSPrithviraj Singha Roy(Director)in

BoardJLJohn Loser(Director)inDBDavid Berry(Director)

Co-investorsCOCourtside VenturesFLFloating PointNONorth South VenturesSTSteelSky VenturesTITime BioVenturesAVAverin Capital+1 more

Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.

BiotechDigital HealthMedical DevicesCharlottesville, US

KEKevin Eisenfrats(Co-Founder and CEO)inJohn Herr(Co-Founder)

BoardIris Van Alderwerelt van Rosenburgh(Director)GBGurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)

PartnerLSLaura Stoppel· quoted

Co-investorsBIBiotechnology Value FundMBMBX CapitalALAllied Venture PartnersAMAmboy Street VenturesAUAurum Venture PartnersBEBeni Venture Capital+15 more

Convergent provides an AI simulation platform for enterprise training and skill development.

AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB

Co-investorsTETechstarsANAndreessen HorowitzOROrbiMed

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.

BiotechHealthtech

GSGeorge Simeon(CEO)inGregory S. Curhan(CFO)GDGuy De La Rosa(CMO)in

Co-investorsADAdjuvant CapitalOROrbiMedSASanofi VenturesHBHBM Healthcare InvestmentsJAJanus Henderson InvestorsMEMedicxi

Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.

BiotechHealthtechCambridge, US

Kevin Mills(Executive Officer, Director)inRGRonald Goldstein(Executive Officer)inDCDonald Corcoran(Executive Officer, Director)inMRMarkus Renschler(Director)in

BoardTimothy Romberger(Director)Barry Mills(Director)

Co-investorsDRDroia VenturesLILightstone VenturesOUOUP (Osage University Partners)ALAlly Bridge GroupDEDe Novo VenturesJAJanus Henderson Investors+3 more

DealForma provides a data platform and analyst support for biopharma business development teams to research partnerships, deals, funding trends, and therapeutic areas.

BiotechData & InfrastructureHealthtechSaaS

Chris

Co-investorsTITinySeedALAlgerREREDMILERTRTW Investments L.P.SOSofinnova Ventures

Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.

BiotechDigital HealthMedical Devices

Co-investorsARArtis VenturesCACasa Verde CapitalNONoeticOMOMX VenturesPSPsyMed VenturesVEVertical Venture Partners+6 more

A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.

BiotechDigital HealthHealthtech

Co-investorsACAccess BiotechnologyBABain Capital Life SciencesOXOxford Bioscience Partners

Dignify Therapeutics develops "on demand" drugs that trigger emptying of the bladder and/or bowel when a person chooses, aimed at restoring control of bowel and bladder function.

BiotechDigital HealthMedical DevicesResearch Triangle Park, US

Edward C Burgard(Executive Officer, Director, Promoter)Karl Thor(Executive Officer, Director, Promoter)inBWBenny Ward(Executive Officer, Director, Promoter)in

BoardFred Eshelman(Director)inDaniel J Ricca(Director, Promoter)Ebrahim Versi(Director, Promoter)

Co-investorsESEshelman Ventures, LLC

The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology.

BiotechHealthtechSan Diego, US

ATArthur T Suckow(Executive Officer)inASArthur Suckow, Ph.D.(Founder)in

Co-investorsACAccess BiotechnologyEXExSight VenturesJAJanus Henderson Investors

Dynelectro commercializes solid oxide electrolysis (SOEC) systems for industrial hydrogen production and energy storage, with modular platforms scaling from 250 kW to multi-megawatt capacity.

CleantechDeep TechEnergyHardware

SHSøren Højgaard Jensenin

Co-investorsTHThe Footprint FirmPSPSVVSVsquared VenturesYAYara Growth Ventures